> > Hospital Pharmacies

Is your hospital ready for bleeds when they happen?

In situations where a patient does not bring their own clotting factor concentrate, MASAC recommends emergency departments have ready access to it within 1 hour upon a patient’s arrival.1

With NovoSeven® RT on hand, your hospital is prepared for the widest range of patients with bleeding disorders.a

Is your hospital ready for bleeds when they happen?

In situations where a patient does not bring their own clotting factor concentrate, MASAC recommends emergency departments have ready access to it within 1 hour upon a patient’s arrival.1

With NovoSeven® RT on hand, your hospital is prepared for the widest range of patients with bleeding disorders.a

NovoSeven® RT Competitive Indication Chart
NovoSeven® RT Competitive Indication Chart

aAs compared to FEIBA and Obizur.
bNovoSeven® RT is a recombinant FVII.
cFEIBA is an activated prothrombin complex concentrate (aPCC).
dObizur is a porcine sequence recombinant FVIII.

NovoSevenRT Packaging

NovoSeven® RT offers features to support hospital use.2

Low-volume dosing and compact packaging to help maximize space

Ability to administer via continuous infusion for perioperative management

Room temperature storage up to 77˚F

Available in 1-mg, 2-mg, 5-mg, and 8-mg vials

Everything needed for reconstitution is in 1 box

Each vial comes with a prefilled syringe, meaning no extra steps to fill a syringe with diluente

eCompared with reconstitution using histidine vials.

NovoSevenRT Packaging
coagulation disorders code icon

Looking for codes for

coagulation disorders?

Get the diagnosis codes

NovoSevenRT vials and dosing

Need dosing

information?

See recommendations

Find a representative

Have a question? We're

here to help.

Find a representative

Available from Novo Nordisk:

Esperoct® logo

Visit website
Prescribing Information

Esperoct® logo

Visit website
Prescribing Information

Rebinyn® logo

Visit website
Prescribing Information

Rebinyn® logo

Visit website
Prescribing Information

Novoeight® logo

Visit website
Prescribing Information

Novoeight® logo

Visit website
Prescribing Information

Tretten® logo

Visit website
Prescribing Information

Tretten® logo

Visit website
Prescribing Information

Selected Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for Prescribing Information

References

  1. National Hemophilia Foundation. MASAC guidelines for emergency department management of individuals with hemophilia and other bleeding disorders, #252. 2017.
  2. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019.
  3. FEIBA [package insert]. Westlake Village, CA: Baxalta US Inc; 2018.
  4. Obizur [package insert]. Westlake Village, CA: Baxalta US Inc; 2020.